Efficacy of injectable transamine in patients with benign prostatic hyperplasia

Evaluation of the effectiveness of injectable transamine administration in reducing the volume of bleeding in open trans-vesicular prostatectomy in patients with benign prostatic hyperplasia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211121053127N1

Enrollment

Registered

2021-12-21

Start date

2021-12-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostate enlargement. Benign neoplasm of prostate

Interventions

Intervention 1: Intervention group: Injectable transamine * Quantity: (1 gram injection during surgery and 48 hours after surgery, 3 times a day injection) After induction of anesthesia, transamine 10

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients undergoing Prostatectomy Patients who are willing to participate in the study

Exclusion criteria

Exclusion criteria: Use of anticoagulants such as aspirin and dipyridamole Prothrombin time and partial thromboplastin time are high for whatever reason Any history of thrombotic events History of bleeding disorders Chronic kidney disease (serum creatinine greater than 180 micromoles per liter).

Design outcomes

Primary

Measure	Time frame
Bleeding volume. Timepoint: 24 hours after surgery. Method of measurement: The amount of ml of blood removed from the patient's body.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Mohammadi sichani

Esfahan University of Medical Sciences

M_mohammadi@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026